ANALYSIS OF NEUROLEPTICS PRESCRIPTION IN SCHIZOPHRENIC PATIENTS WITH THE USE OF ‘QUALITY INDICATORS’ IN A PSYCHIATRIC HOSPITAL

Abstract

292 case records of schizophrenic patients between 2005 and 2007 have been investigated for the purpose of identification of significant differences in frequency and reason of prescription of typical and atypical neuroleptics in the conditions of a psychiatric hospital with clinical and follow-up methods with use of “quality indicators”. During investigation, statistically significant results of major efficiency and safety of second generation neuroleptics in therapy of schizophrenic patients in the studied years have been shown. The indicators of prescription of original and generic agents are analyzed; evaluation of polypharmacy and combined therapy in schizophrenic patients is given.

Keywords

treatment of schizophrenic patients / “quality indicators” / typical neuroleptics / atypical neuroleptics / polypharmacy

References

[1] Ахмерова И.Ю. Клинико-эпидемиологическое и молекулярно-генетическое исследование шизофрении в Республике Башкортостан: дисс. … канд. мед. наук. М., 2012. 131 с.

[2] Волков В.П. Соматическая патология и причины смерти при шизофрении // Журнал неврологии и психиатрии. 2009. № 5. С. 14-19.

[3] Гурович И.Я., Шмуклер А.Б. Шизофрения в систематике психических расстройств // Социальная и клиническая психиатрия. 2014. Т. 24, вып. 2. С. 46-49.

[4] Джонс П.Б., Бакли П.Ф., Мосолов С.Н. Шизофрения: Клинич. руководство [Пер. с англ. под общ. ред. С.Н. Мосолова]. М., 2008.

[5] Краснов В.Н. Стандарты оказания помощи больным шизофренией [Под ред. В.Н. Краснова, И.Я. Гуровича, С.Н. Мосолова, А.Б. Шмуклера]. М., 2006.

[6] Краснов В.Н., Психиатрическая помощь больным шизофренией. Клиническое руководство. М.: Медпрактика, 2007. С. 260.

[7] Alam D.A., Janicak P.G. The role of psychopharmacotherapy in improving the long-term outcome of schizophrenia // Essent. Psychopharmacol. 2005. Vol. 6. (Suppl. 3). P. 127-140.

[8] Beary M., Wildgust H.J. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications // J. Psychopharmacol. 2012. Vol. 26. (Suppl. 5). P. 52-61.

[9] Harvey P.D. Disability in schizophrenia: contributing factors and validated assessments // J. Clin. Psychiatry. 2014. Vol. 75, Suppl. 1. P. 15-20.

[10] Olesen J., Gustavsson A., Svensson M. et al. The economic cost of brain disorders in Europe // Eur. J. Neurol. 2012. Vol. 19 (Suppl. 1). P. 155-162.

RIGHTS & PERMISSIONS

Altynbekov K.S.